Stock PCSA PROCESSA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.48 USD -6.33% Intraday chart for Processa Pharmaceuticals, Inc. -15.91% -77.88%
May. 10 Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 30 Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Top Midday Gainers
MT
HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target
MT
Benchmark Adjusts Price Target on Processa Pharmaceuticals to $4 From $9, Keeps Speculative Buy Rating
MT
Oppenheimer Adjusts Processa Pharmaceuticals Price Target to $3 From $5, Maintains Outperform Rating
MT
Maxim Adjusts Price Target on Processa Pharmaceuticals to $5 From $9, Maintains Buy Rating
MT
Oppenheimer Adjusts Processa Pharmaceuticals' Price Target to $11 From $17, Maintains Outperform Rating
MT
Maxim Initiates Processa Pharmaceuticals at Buy with $9 Price Target
MT
PROCESSA PHARMACEUTICALS : Oppenheimer Starts Processa Pharmaceuticals at Outperform With $20 Price Target
MT
PROCESSA PHARMACEUTICALS : Benchmark Starts Processa Pharmaceuticals at Buy with $15 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCSA Stock
  4. News Processa Pharmaceuticals, Inc.
  5. Analyst Reco.